Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Copyright © 2024 American Chemical Society
April 1, 2024 Cover
Volume 102, Issue 10
Long touted as a means to speed up the discovery of new ways to identify tumors, the technology also comes with a bunch of caveats
Volume 102 |
Issue 10
To battle B-cell cancers, drugmakers are going beyond the covalent bond
Noncovalent BTK inhibitors sidestep resistance that arises from first-line treatments
What are eclipse glasses, and how do they keep your eyes safe during an eclipse?
These cardboard-and-plastic glasses may seem flimsy, but they keep dangerous reactions from destroying your eyes
-
Carolyn Pearce wants to convert the US’s largest nuclear waste dump to glass
Understanding the complex chemistry is the key to the safe long-term storage of the US’s nuclear waste legacy
-
Why some human brains don’t break down after thousands of years
An unexplored mechanism may explain how human brains can be preserved for up to 12,000 years
-
War has deteriorated Ukraine’s science sector
Restoring damaged buildings and scientific equipment will cost Ukraine $1.26 billion
ADVERTISEMENT
US puts $6 billion toward industrial decarbonization
Department of Energy to fund projects from BASF, Dow, and other big chemical firms
Business & Policy Concentrates
- FDA approves first-in-class drug for rare lung disorder
- Clasp Therapeutics launches with $150 million in hand
- Removing institutional information from grant application materials could reduce reviewers’ bias
- War has deteriorated Ukraine’s science sector
- At DCAT, firms sought to capitalize on WuXi woes
